The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Anthony P Adamis - One of the best experts on this subject based on the ideXlab platform.
-
increased vascular endothelial growth factor levels in the vitreous of eyes with Proliferative Diabetic Retinopathy
American Journal of Ophthalmology, 1994Co-Authors: Anthony P Adamis, Joan W Miller, Mariateresa Bernal, Donald J Damico, Judah Folkman, Tetkin Yeo, Kiangteck J YeoAbstract:The vitreous levels of the angiogenic polypeptide vascular endothelial growth factor (also known as vascular permeability factor) were measured and compared in eyes with and without Proliferative Diabetic Retinopathy. Undiluted vitreous samples from 20 eyes were collected at the time of vitrectomy, and vascular endothelial growth factor levels were determined by using a time-resolved immunofluorometric assay. Vitreous vascular endothelial growth factor levels were significantly higher in eyes with Proliferative Diabetic Retinopathy than in eyes without Proliferative Diabetic Retinopathy (P = .006; Wilcoxon Rank Sum Test). The median vitreous concentration in the eyes with Proliferative Diabetic Retinopathy was 29.1 pM and exceeded the known concentration required for the maximal proliferation of vascular endothelial cells in vitro. These data are consistent with vascular endothelial growth factor serving as a physiologically relevant angiogenic factor in Proliferative Diabetic Retinopathy.
Kiangteck J Yeo - One of the best experts on this subject based on the ideXlab platform.
-
increased vascular endothelial growth factor levels in the vitreous of eyes with Proliferative Diabetic Retinopathy
American Journal of Ophthalmology, 1994Co-Authors: Anthony P Adamis, Joan W Miller, Mariateresa Bernal, Donald J Damico, Judah Folkman, Tetkin Yeo, Kiangteck J YeoAbstract:The vitreous levels of the angiogenic polypeptide vascular endothelial growth factor (also known as vascular permeability factor) were measured and compared in eyes with and without Proliferative Diabetic Retinopathy. Undiluted vitreous samples from 20 eyes were collected at the time of vitrectomy, and vascular endothelial growth factor levels were determined by using a time-resolved immunofluorometric assay. Vitreous vascular endothelial growth factor levels were significantly higher in eyes with Proliferative Diabetic Retinopathy than in eyes without Proliferative Diabetic Retinopathy (P = .006; Wilcoxon Rank Sum Test). The median vitreous concentration in the eyes with Proliferative Diabetic Retinopathy was 29.1 pM and exceeded the known concentration required for the maximal proliferation of vascular endothelial cells in vitro. These data are consistent with vascular endothelial growth factor serving as a physiologically relevant angiogenic factor in Proliferative Diabetic Retinopathy.
Yasutaka Uchihori - One of the best experts on this subject based on the ideXlab platform.
-
Severe Proliferative Diabetic Retinopathy associated with acromegaly
The British journal of ophthalmology, 1999Co-Authors: Naoki Inokuchi, Tsunehiko Ikeda, Fuyuko Yasuda, Setuko Shirai, Yasutaka UchihoriAbstract:Acromegaly is complicated by diabetes mellitus because of the action of growth hormone (GH) which induces the production of insulin-like growth factor I (IGF-I). IGF-I may contribute to the development of Diabetic Retinopathy in an autocrine and/or paracrine manner.1 In patients with acromegaly who demonstrate excessive secretion of GH, the incidence of Retinopathy is reportedly very low and severe Retinopathy is rare.2 3 This report describes a patient with severe Proliferative Diabetic Retinopathy in both eyes associated with acromegaly. We performed pars plana vitrectomy and calculated the levels of angiogenic growth factors (IGF-I and vascular endothelial growth factor, VEGF) in the vitreous of both eyes to learn whether GH and/or IGF-I may influence the progression of Diabetic Retinopathy in Proliferative Diabetic Retinopathy associated with acromegaly.4 5 ### CASE REPORT A 62 year old woman presented with severe Proliferative Diabetic Retinopathy and was admitted to Osaka Kaisei Hospital for a pars plana vitrectomy. The …
Tomoaki Murakami - One of the best experts on this subject based on the ideXlab platform.
-
Novel role of erythropoietin in Proliferative Diabetic Retinopathy
Diabetes Research and Clinical Practice, 2007Co-Authors: Hitoshi Takagi, Daisuke Watanabe, Kiyoshi Suzuma, Masafumi Kurimoto, Izumi Suzuma, Hirokazu Ohashi, Tomonari Ojima, Tomoaki MurakamiAbstract:Diabetic Retinopathy is a leading cause of visual disturbance in adults. In Proliferative Diabetic Retinopathy, ischemia-induced pathologic growth of new blood vessels often causes catastrophic loss of vision. Besides VEGF, the existence of another potent ischemia-induced angiogenic factor is postulated. Since ischemia-inducible erythropoietin (Epo) has recently been identified its angiogenic properties, we investigated its potential role during retinal angiogenesis in Proliferative Diabetic Retinopathy (PDR). The vitreous Epo level in patients with PDR was significantly higher than that in nonDiabetic patients. Multivariate logistic regression analyses indicated that Epo and VEGF were independently associated with PDR and that Epo was more strongly associated with PDR than VEGF. Blockade of Epo inhibits retinal neovascularization in vivo, and inhibits endothelial cell proliferation response to PDR vitreous in vitro. Our data provide strong evidence that erythropoietin is a potent retinal angiogenic factor independent of VEGF and is capable of stimulating ischemia-induced retinal angiogenesis in Proliferative Diabetic Retinopathy. Inhibition of such molecular mechanisms in the retinal angiogenesis could be a new therapeutical strategy in halting or preventing pathologic angiogenesis in Diabetic Retinopathy.
-
erythropoietin as a retinal angiogenic factor in Proliferative Diabetic Retinopathy
The New England Journal of Medicine, 2005Co-Authors: Daisuke Watanabe, Kiyoshi Suzuma, Shigeyuki Matsui, Masafumi Kurimoto, Junichi Kiryu, Mihori Kita, Izumi Suzuma, Hirokazu Ohashi, Tomonari Ojima, Tomoaki MurakamiAbstract:background Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. methods We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous Proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. results The median vitreous erythropoietin level in 73 patients with Proliferative Diabetic Retinopathy was significantly higher than that in 71 patients without diabetes (464.0 vs. 36.5 mIU per milliliter, P<0.001). The median VEGF level in patients with Retinopathy was also significantly higher than that in patients without diabetes (345.0 vs. 3.9 pg per milliliter, P<0.001). Multivariate logistic-regression analyses indicated that erythropoietin and VEGF were independently associated with Proliferative Diabetic Retinopathy and that erythropoietin was more strongly associated with the presence of Proliferative Diabetic Retinopathy than was VEGF. Erythropoietin and VEGF gene-expression levels are up-regulated in the murine ischemic retina, and the blockade of erythropoietin inhibits retinal neovascularization in vivo and endothelial-cell proliferation in the vitreous of patients with Diabetic Retinopathy in vitro. conclusions Our data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in Proliferative Diabetic Retinopathy.
Mario R Romano - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal bevacizumab for surgical treatment of severe Proliferative Diabetic Retinopathy
Graefes Archive for Clinical and Experimental Ophthalmology, 2010Co-Authors: Raffaello Di Lauro, Pio De Ruggiero, Raffaella Di Lauro, Maria Teresa Di Lauro, Mario R RomanoAbstract:Background The purpose of this study is to evaluate the role, the safety and the effectiveness of intravitreal bevacizumab (IVB) injections as an adjunct to vitrectomy in the management of severe Proliferative Diabetic Retinopathy (PDR).
